Key result
High-sensitivity troponin I was associated with incident atrial fibrillation but did not improve prediction beyond classical risk factors and NT-proBNP.
Why the study?
Traditional cardiovascular risk factors do not explain all atrial fibrillation cases, and biomarkers reflecting cardiac injury such as hsTnI may help close this gap.
Does high-sensitivity troponin I (hsTnI) improve prediction of incident atrial fibrillation beyond traditional cardiovascular risk factors in community cohorts?
Cohort (n=45,298)
Yes
Does high-sensitivity troponin I (hsTnI) improve prediction of incident atrial fibrillation beyond traditional cardiovascular risk factors in community cohorts?
Answers are grounded in this paper and cite their sources.
hsTnI is associated with incident AF, heart failure, and mortality, but does not meaningfully improve AF risk prediction beyond traditional risk factors and NT-proBNP.
AIMS: Atrial fibrillation (AF) is becoming increasingly common. Traditional cardiovascular risk factors (CVRF) do not explain all AF cases. Blood-based biomarkers reflecting cardiac injury such as high-sensitivity troponin I (hsTnI) may help close this gap. METHODS: We investigated the predictive ability of hsTnI for incident AF in 45,298 participants (median age 51.4 years, 45.0% men) across European community cohorts in comparison to CVRF and established biomarkers (C-reactive protein, N-terminal pro B-type natriuretic peptide). RESULTS: During a median follow-up of 7.7 years, 1734 (3.8%) participants developed AF. Those in the highest hsTnI quarter (≥4.2 ng/L) had a 3.91-fold (95% confidence interval (CI) 3.30, 4.63; p < .01) risk for developing AF compared to the lowest quarter (<1.4 ng/L). In multivariable-adjusted Cox proportional hazards models a statistically significant association was seen between hsTnI and AF (hazard ratio (HR) per 1 standard deviation (SD) increase in log10(hsTnI) 1.08; 95% CI 1.01, 1.16; p = .03). Inclusion of hsTnI did improve model discrimination (C-index CVRF 0.811 vs. C-index CVRF and hsTnI 0.813; p < .01). Higher hsTnI concentrations were associated with heart failure (HR per SD 1.37; 95% CI 1.12, 1.68; p < .01) and overall mortality (HR per SD 1.24; 95% CI 1.09, 1.41; p < .01). CONCLUSION: hsTnI as a biomarker of myocardial injury does not improve prediction of AF incidence beyond classical CVRF and NT-proBNP. However, it is associated with the AF-related disease heart failure and mortality likely reflecting underlying subclinical cardiovascular impairment.
No takes yet. Share an insight, caveat, or question.
Börschel et al. (2023) conducted a cohort in Incident atrial fibrillation (n=45,298). High-sensitivity troponin I (hsTnI) vs. Traditional cardiovascular risk factors and established biomarkers was evaluated on Incident atrial fibrillation (HR 1.08, 95% CI 1.01, 1.16, p=0.03). High-sensitivity troponin I was associated with incident atrial fibrillation but did not improve prediction beyond classical risk factors and NT-proBNP.
Synapse has enriched 10 related papers. Consider them for comparative context: